@article{08823e658da945eda51f394cfc48f7b2,
title = "Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation",
abstract = "Atrial fibrillation (AF) is a common cardiac arrhythmia associated with high mortality and morbidity. Current treatments of AF have limited efficacy and considerable side effects. Histone deacetylases (HDACs) play critical roles in the pathophysiology of cardiovascular diseases and contribute to the genesis of AF. Therefore, HDAC inhibition may prove a novel therapeutic strategy for AF through upstream therapy and modifications of AF electrical and structural remodeling. In this review, we provide an update of the knowledge of the effects of HDACs and HDAC inhibitors on AF, and dissect potential underlying mechanisms.",
keywords = "Atrial fibrillation, HDAC inhibitors, Histone deacetylases, Non-histone proteins",
author = "Baigalmaa Lkhagva and Kao, {Yu Hsun} and Chen, {Yao Chang} and Chao, {Tze Fan} and Chen, {Shih Ann} and Chen, {Yi Jen}",
note = "Funding Information: The present work was supported by grants from the National Science Council , Taiwan ( NSC100-2628-B-038-001-MY4 , NSC102-2314-B-038-003-MY2 , NSC102-2325-B-010-005 , and NSC102-2628-B-038-002-MY3 ), and Wan Fang Hospital, Taipei Medical University ( 104-wf-eva-01 , 104swf01 , and 105swf09 ). ",
year = "2016",
doi = "10.1016/j.ejphar.2016.04.034",
language = "English",
volume = "781",
pages = "250--257",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
}
